Virogin Biotech

Notch Therapeutics is a biotechnology company focused on the development of innovative cell therapies for cancer treatment. The company utilizes a proprietary gene-editing technology known as Engineered Thymic Niche (ETN) to engineer and manufacture T cells for targeted cancer therapies.

The ETN platform developed by Notch Therapeutics enables precise control over the programming of T cells, allowing for the generation of customized, tumor-targeting immune cells. By utilizing this platform, the company aims to develop next-generation allogeneic (off-the-shelf) cell therapies with improved efficacy and safety profiles.

One of the key advantages of Notch Therapeutics' approach is its ability to generate T cells that are designed to specifically recognize and eliminate cancer cells while minimizing damage to healthy tissues. This targeted approach has the potential to enhance the therapeutic response and reduce side effects associated with traditional cancer treatments.

Notch Therapeutics is also working on expanding its technology to develop therapies for other diseases beyond cancer. By harnessing the power of gene editing and cellular engineering, the company aims to address unmet medical needs and provide new treatment options for patients.

Headquarters: Vancouver, Canada, and Shanghai, China

Founded: 2015

Website: https://virogin.com/